OTSUKA AMERICA PHARMACEUTICAL, INC. for OTSUKA AMERICA PHARMACEUTICAL, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.
Foreign entity interest: Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN DWIGHT | — |
| SOFIA FOX | — |
Health Issues HCR
Support HELP Co-Pays Act (H.R. 308). Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinate care, mental health equity, PBM transparency, and 340B reform. FY2024 Labor, HHS, Education, and Related Agencies Appropriations (funding for PTSD). FY2024 Agriculture, FDA, and Related Agencies Appropriations (box warning report language).
Foreign entity interest: Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN DWIGHT | — |
| SOFIA FOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.